Nicox’s NCX 470 Mont Blanc Phase 3 Glaucoma Trial Reaches 50% Enrollment Milestone - Seite 3

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com. Analyst coverage  

Bryan, Garnier & Co                Victor Floc’h                Paris, France
Cantor Fitzgerald                    Louise Chen                New York, U.S.
Edison Investment Research Pooya Hemami            London, UK
H.C. Wainwright & Co             Yi Chen                        New York, U.S.
Kepler Cheuvreux                    Damien Choplain        Paris, France

    The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current.  Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts Nicox
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development 
T [phone]
[e-mail] Investors & Media
United States & Europe
LifeSci Advisors, LLC
Mary-Ann Chang
T [phone]
[e-mail] Media
France
LifeSci Advisors, LLC
Sophie Baumont
M [phone]
[e-mail] Forward-Looking Statements The information contained in this document may be modified without prior notice.  This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance.  These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.  Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.